Osteonecrosis of the jaw: Dental outcomes in metastatic breast cancer patients treated with bisphosphonates with/without bevacizumab

Clinical Breast Cancer

Volumn 11, Issue 4, 2011, Pages 252-257

  Ngamphaiboon, Nuttapong ^a   Frustino, Jennifer L ^a   Kossoff, Ellen B ^a   Sullivan, Maureen A ^a   O'Connor, Tracey L ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Bevacizumab; Bisphosphonates; Dental outcomes; Metastatic breast cancer; Osteonecrosis of the jaw

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; BEVACIZUMAB; CHLORHEXIDINE GLUCONATE; CIPROFLOXACIN; CLINDAMYCIN; LEVOFLOXACIN; PAMIDRONIC ACID; PENICILLIN DERIVATIVE; ZOLEDRONIC ACID;

ADULT; AGED; ANTIBIOTIC THERAPY; BREAST CANCER; CANCER REGRESSION; CLINICAL ARTICLE; DEBRIDEMENT; DENTAL CARE; EDENTULOUSNESS; HUMAN; JAW OSTEONECROSIS; JAW PAIN; METASTASIS; OUTCOMES RESEARCH; PARESTHESIA; PERIODONTAL DISEASE; REVIEW; SWELLING;

EID: 80052746518     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.1016/j.clbc.2011.02.001     Document Type: Article

References (38)

1. A. Badros, D. Weikel, and A. Salama Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors J Clin Oncol 24 2006 945 952 (Pubitemid 46638849)
2. K. Vahtsevanos, A. Kyrgidis, and E. Verrou Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw J Clin Oncol 27 2009 5356 5362
3. K. Zervas, E. Verrou, and Z. Teleioudis Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients Br J Haematol 134 2006 620 623 (Pubitemid 44253605)
4. A. Bamias, E. Kastritis, and C. Bamia Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors J Clin Oncol 23 2005 8580 8587 (Pubitemid 46211499)
5. S.B. Woo, J.W. Hellstein, and J.R. Kalmar Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws Ann Intern Med 144 2006 753 761 (Pubitemid 46780635)
6. T. Hansen, M. Kunkel, and A. Weber Osteonecrosis of the jaws in patients treated with bisphosphonates - histomorphologic analysis in comparison with infected osteoradionecrosis J Oral Pathol Med 35 2006 155 160
7. D.A. Tipton, B.A. Seshul, and M. Dabbous Effect of bisphosphonates on human gingival fibroblast production of mediators of osteoclastogenesis: RANKL, osteoprotegerin and interleukin-6 J Periodontal Res 46 2011 39 47
8. S. Pozzi, S. Vallet, and S. Mukherjee High-dose zoledronic acid impacts bone remodeling with effects on osteoblastic lineage and bone mechanical properties Clin Cancer Res 15 2009 5829 5839
9. I. Holt, M.J. Marshall, and M.W. Davie Pamidronate stimulates recruitment and decreases longevity of osteoclast nuclei in mice Semin Arthritis Rheum 23 1994 263 264 (Pubitemid 24077105)
10. M. Mayahara, and T. Sasaki Cellular mechanism of inhibition of osteoclastic resorption of bone and calcified cartilage by long-term pamidronate administration in ovariectomized mature rats Anat Rec A Discov Mol Cell Evol Biol 274 2003 817 826 (Pubitemid 37238380)
11. E.R. Van Beek, C.W. Lowik, and S.E. Papapoulos Bisphosphonates suppress bone resorption by a direct effect on early osteoclast precursors without affecting the osteoclastogenic capacity of osteogenic cells: the role of protein geranylgeranylation in the action of nitrogen-containing bisphosphonates on osteoclast precursors Bone 30 2002 64 70 (Pubitemid 34044302)
12. M.R. Allen, and D.B. Burr The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data J Oral Maxillofac Surg 67 2009 61 70
13. L.P. Garetto, J. Chen, and J.A. Parr Remodeling dynamics of bone supporting rigidly fixed titanium implants: a histomorphometric comparison in four species including humans Implant Dent 4 1995 235 243
14. Z.H. Han, S. Palnitkar, and D.S. Rao Effects of ethnicity and age or menopause on the remodeling and turnover of iliac bone: implications for mechanisms of bone loss J Bone Miner Res 12 1997 498 508 (Pubitemid 27155209)
15. S.S. Huja, S.A. Fernandez, and K.J. Hill Remodeling dynamics in the alveolar process in skeletally mature dogs Anat Rec A Discov Mol Cell Evol Biol 288 2006 1243 1249 (Pubitemid 44901865)
16. M.R. Allen, and D.B. Burr Mandible matrix necrosis in beagle dogs after 3 years of daily oral bisphosphonate treatment J Oral Maxillofac Surg 66 2008 987 994 (Pubitemid 351522818)
17. D. Santini, M. Caraglia, and B. Vincenzi Mechanisms of disease: preclinical reports of antineoplastic synergistic action of bisphosphonates Nat Clin Pract Oncol 3 2006 325 338 (Pubitemid 43871543)
18. A. Allegra, A. Alonci, and G. Penna Bisphosphonates induce apoptosis of circulating endothelial cells in multiple myeloma patients and in subjects with bisphosphonate-induced osteonecrosis of the jaws Acta Haematol 124 2010 79 85
19. T. Ziebart, A. Pabst, and M.O. Klein Bisphosphonates: restrictions for vasculogenesis and angiogenesis: inhibition of cell function of endothelial progenitor cells and mature endothelial cells in vitro Clin Oral Investig 15 1 2011 105 111
20. M.A. Scheper, A. Badros, and R. Chaisuparat Effect of zoledronic acid on oral fibroblasts and epithelial cells: a potential mechanism of bisphosphonate-associated osteonecrosis Br J Haematol 144 2009 667 676
21. D. Santini, B. Vincenzi, and G. Avvisati Pamidronate induces modifications of circulating angiogenetic factors in cancer patients Clin Cancer Res 8 2002 1080 1084 (Pubitemid 34517643)
22. P. Fournier, S. Boissier, and S. Filleur Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats Cancer Res 62 2002 6538 6544 (Pubitemid 35364119)
23. G. Ferretti, A. Fabi, and P. Carlini Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients Oncology 69 2005 35 43 (Pubitemid 41207056)
24. D. Santini, B. Vincenzi, and G. Dicuonzo Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients Clin Cancer Res 9 2003 2893 2897 (Pubitemid 36993246)
25. C.L. Estilo, M. Fornier, and A. Farooki Osteonecrosis of the jaw related to bevacizumab J Clin Oncol 26 2008 4037 4038
26. S. Greuter, F. Schmid, and T. Ruhstaller Bevacizumab-associated osteonecrosis of the jaw Ann Oncol 19 2008 2091 2092
27. C. Christodoulou, A. Pervena, and G. Klouvas Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone Oncology 76 2009 209 211
28. J.B. Aragon-Ching, Y.M. Ning, and C.C. Chen Higher incidence of osteonecrosis of the jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents Cancer Invest 27 2009 221 226
29. V. Guarneri, D. Miles, and N. Robert Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer Breast Cancer Res Treat 122 2010 181 188
30. H.L. McArthur, C. Estilo, and J. Huryn Osteonecrosis of the jaw (ONJ) among intravenous (IV) bisphosphonate- and/or bevacizumab-treated patients (pts) at Memorial Sloan-Kettering Cancer Center (MSKCC) J Clin Oncol 26 suppl 2008 (abstr 9588)
31. S.L. Ruggiero, T.B. Dodson, and L.A. Assael American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws - 2009 update J Oral Maxillofac Surg 67 2009 2 12
32. T. Fehm, D. Felsenberg, and M. Krimmel Bisphosphonate-associated osteonecrosis of the jaw in breast cancer patients: recommendations for prevention and treatment Breast 18 2009 213 217
33. E. Van Cutsem, F. Rivera, and S. Berry Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study Ann Oncol 20 2009 1842 1847
34. S. Geiger-Gritsch, B. Stollenwerk, and R. Miksad Safety of bevacizumab in patients with advanced cancer: a meta-analysis of randomized controlled trials Oncologist 15 2010 1179 1191
35. T.S. Lazarovici, R. Yahalom, and S. Taicher Bisphosphonate-related osteonecrosis of the jaws: a single-center study of 101 patients J Oral Maxillofac Surg 67 2009 850 855
36. V. Thumbigere-Math, M.C. Sabino, and R. Gopalakrishnan Bisphosphonate-related osteonecrosis of the jaw: clinical features, risk factors, management, and treatment outcomes of 26 patients J Oral Maxillofac Surg 67 2009 1904 1913
37. C.I. Ripamonti, M. Maniezzo, and T. Campa Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates The experience of the National Cancer Institute of Milan Ann Oncol 20 2009 137 145
38. M.A. Dimopoulos, E. Kastritis, and C. Bamia Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid Ann Oncol 20 2009 117 120